Amgen Bone Drug Shows Heart Risks in Trial

May 22, 2017

Reuters

Amgen and UCB SA's experimental osteoporosis drug, Evenity, will struggle to to win U.S. FDA approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

Details were not disclosed, however Amgen revealed on Sunday that the drug raised unexpected heart-safety concerns.

The new safety data will have to be taken into consideration, delaying a decision from the FDA. The Agency had been expected to make a ruling in July.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments